Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference
Aclaris Therapeutics (ACRS) will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 16 in London.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aclaris Therapeutics (ACRS) will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 16 in London.
CEO Dr. Neal Walker and other senior leadership members will join the discussion at 10:30 AM GMT (5:30 AM ET). A live and archived webcast will be accessible through the Events page at www.aclaristx.com, with the recording available for at least 30 days.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Monday November 16 at 10:30 AM GMT (5:30 AM ET), Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Jefferies Global Healthcare Conference in London, UK.
A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
